RIPK1 and COVID-19: Since inhibition of RIPK1 can reduce the replication of both 323P and 323L SARS-CoV-2 in human lung organoids, our results suggest that RIPK1 kinase inhibitors may provide an effective therapy for severe COVID-19 as well as reducing the spread of SARS-CoV-2 variants.